Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

Fingerprint

Dive into the research topics of 'Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this